The cyclin kinase inhibitor p21(WAF1/CIP1) is required for glomerular hypertrophy in experimental diabetic nephropathy

Kidney International

Volumn 56, Issue 5, 1999, Pages 1691-1699

  Al Douahji, Mouhannad ^a,b   Brugarolas, James ^a,b   Brown, Paul A J ^a,b   Stehman Breen, Catherine O ^a,b   Alpers, Charles E ^a,b   Shankland, Stuart J ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Cyclin; Diabetes; Glomerulus; Hypertrophy; P21; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXPERIMENTAL DIABETES MELLITUS; GLOMERULUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032704528     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00728.x     Document Type: Article

References (55)

1. 1. NATIONAL INSTITUTES OF HEALTH: Renal Data System. Bethesda, 1996
2. 2. OSTERBY R, GUNDERSEN HJ: Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia 11:225-229, 1975
3. 3. MAUER SM: Structural-functional correlations of diabetic nephropathy. Kidney Int 45:612-622, 1994
4. 4. SEYER-HANSEN K: Renal hypertrophy in streptozotocin-diabetic rats. Clin Sci Mol Med Suppl 51:551-555, 1976
5. 5. SEYER-HANSEN K: Renal hypertrophy in experimental diabetes mellitus. Kidney Int 23:643-646, 1983
6. 6. BILOUS RW, MAUER SM, SUTHERLAND DE, STEFFES MW: Mean glomerular, and rate of development of diabetic nephropathy. Diabetes 38:1142-1147, 1989
7. 7. YOUNG BA, JOHNSON RJ, ALPERS CE, ENG E, GORDON K, FLOEGE J, COUSER WG, SEIDEL K: Cellular events in the evolution of experimental diabetic nephropathy. Kidney to 47:935-944, 1995
8. 8. RABKIN R, FERVENZA FC: Renal hypertrophy and kidney disease in diabetes. Diabetes Metab Rev 12:217-241, 1996
9. 9. SCHWIEGER J, FINE LG: Renal hypertrophy, growth factors, and nephropathy in diabetes mellitus. Semin Nephrol 10:242-253, 1990
10. 10. PREISIG PA, FRANCH HA: Renal epithelial cell hyperplasia and hypertrophy. Semin Nephrol 15:327-340, 1995
11. 11. FIORETTO P, STEFFES MW, SUTHERLAND DE, GOETZ FC, MAUER M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75, 1998
12. 12. SHANKLAND SJ, SCHOLEY JW: Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int 46:430-442, 1994
13. 13. SHARMA K, JIN Y, GUO J, ZIYADEH FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530, 1996
14. 14. YAMAMOTO T, NAKAMURA T, NOBLE NA, RUOSLAHTI E, BORDER WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818, 1993
15. 15. ZIYADEH FN, SHARMA K: Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy. Kidney Int 51:S34-S36, 1995
16. 16. SHARMA K, ZIYADEH FN: Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 267:F1094-F2001, 1994
17. 17. HANEDA M, ARAKI S, TOGAWA M, SUGIMOTO T, ISONO M, KIKKAWA R: Activation of mitogen-activated protein kinase cascade in diabetic glomeruli and mesangial cells cultured under high glucose conditions. Kidney Int 51(Suppl 60):S66-S69, 1997
18. 18. INGRAM AJ, SCHOLEY JW: Protooncogene expression and diabetic kidney injury. Kidney Int 51(Suppl 60):S70-S76, 1997
19. 19. WILMER WA, COSIO FG: DNA binding of activator protein-1 is increased in human mesangial cells cultured in high glucose concentrations. Kidney Int 53:1172-1181, 1998
20. 20. SHANKLAND SJ, SCHOLEY JW: Expression of growth-related protooncogenes during diabetic renal hypertrophy. Kidney Int 47:782-788, 1995
21. 21. PARDEE AB: G1 events and regulation of cell proliferation. Science 246:603-608, 1989
22. 22. HUNT T: Cyclins and their partners: From a simple idea to complicated reality. Semin Cell Biol 2:213-222, 1991
23. 23. SHERR CJ, ROBERTS JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995
24. INK4H is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257-261, 1994
25. 25. SERRANO M, HANNON GJ, BEACH D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
26. 26. HARPER JW, ADAMI GR, WEI N, KEYOMARSI K, ELLEDGE SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993
27. 27. HARPER JW, ELLEDGE SJ, KEYOMARSI K, DYNLACHT B, TSAI LH, ZHANG P, DOBROWOLSKI S, BAI C, CONNELL-CROWLEY L, SWINDELL E: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400, 1995
28. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22, 1994
29. KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387:151-158, 1997
30. WAF1,CIP1 is increased in experimental diabetic nephropathy: Potential role in glomerular hypertrophy. J Am Soc Nephrol 9:986-993, 1998
31. 31. BRADLEY GM, BENSON ES: Examination of the urine, in Sanford Clinical Diagnosis (15th ed), edited by DAVIDSON I, HENRY JB, Philadelphia, W.B. Saunders, 1974
32. 32. WEIBEL ER, GOMEZ DM: A principle for counting tissue structures on random sections. J Appl Physiol 17:343-348, 1962
33. 33. PINTO JA, BREWER DB: Glomerular morphometry. I. Combined light and electron microscope studies in normal rats. Lab Invest 30:657-663, 1974
34. 34. BAKER AJ, MOONEY A, HUGHES J, LOMBARDI D, JOHNSON RJ, SAVILL J: Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 94:2105-2116, 1994
35. 35. SHANKLAND SJ, FLOEGE J, THOMAS SE, NANGAKU M, HUGO C, PIPPIN J, HENNE K, HOCKENBERRY DM, JOHNSON RJ, COUSER WG: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 52:404-413, 1997
36. 36. DERYNCK R, JARRETT JA, CHEN EY, GOEDDEL DV: The murine transforming growth factor-beta precursor. J Biol Chem 261:4377-4379, 1986
37. 37. PELTON RW, SAXENA B, JONES M, MOSES HL, GOLD LI: Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: Expression patterns suggest multiple roles during embryonic development. J Cell Biol 115:1091-2105, 1991
38. 38. O'BRIEN KD, GORDON D, DEER S, FERGUSON M, CHAIT A: Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J Clin Invest 89:1544-1550, 1992
39. 39. KLEINMAN KS, FINE LG: Prognostic implications of renal hypertrophy in diabetes mellitus. Diabetes Metab Rev 10:242-253, 1998
40. 40. WOLF G, SCHROEDER R, ZIYADEH FN, THAISS F, ZAHNER G, STAHL RAK: High glucose stimulates expression of p27Kip 1 in cultured mouse mesangial cells: Relationship to hypertrophy. Am J Physiol 42:F348-F356, 1997
41. Kip1 in diabetic db/db mouse: Role of hyperglycemia. Kidney Int 53:869-879, 1998
42. Kip1. Kidney Int 50:2112-2119, 1996
43. 43. PAGTALUNAN ME, MILLER PL, JUMPING-EAGLE S, NELSON RG, MYERS BD, RENNKE HG, COPLON NS, SUN L, MEYER TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99:342-348, 1997
44. WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 101:777-782, 1998
45. 45. JAFFER F, SAUNDERS C, SHULTZ P, THROCKMORTON D, WEINSHELL E, ABBOUD HE: Regulation of mesangial cell growth by polypeptide mitogens: Inhibitory role of transforming growth factor beta. Am J Pathol 135:261-269, 1989
46. 46. FRANCH HA, SHAY JW, ALPERN RJ, PREISIG PA: Involvement of pRB family in TGF-β-dependent epithelial cell hypertrophy. J Cell Biol 129:245-254, 1995
47. 47. CHOI ME, KIM EG, HUANG Q, BALLERMANN BJ: Rat mesangial cell hypertrophy in response to transforming growth factor-beta 1. Kidney Int 44:948-958, 1993
48. 48. WOLF G, SHARMA K, CHEN Y, ERICKSEN M, ZIYADEH FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF beta. Kidney Int 42:647-656, 1992
49. 49. PARK IS, KIYOMOTO H, ABBOUD SL, ABBOUD HE: Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46:473-480, 1997
50. 50. REYNISDOTTIR I, POLYAK K, IAVARONE A, MASSAGUE J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9:1831-1845, 1995
51. 51. LI CY, SUARDET L, LITTLE JB: Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 270:4971-4974, 1995
52. 52. DATTO MB, LI Y, PANUS JF, HOWE DJ, XIONG Y, WANG XF: Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545-5549, 1995
53. 53. STRIKER GE, EASTMAN RD, STRIKER LJ: Diabetic nephropathy: Molecular analysis of extracellular matrix and clinical studies update. Nephrol Dial Transplant 11(Suppl 5):58-61, 1996
54. 54. ZHENG F, STRIKER GE, ESPOSITO C, LUPIA E, STRIKER LJ: Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int 54:1999-2007, 1998
55. 55. MEYER TW: Mechanisms of proteinuria in diabetic renal disease. Semin Nephrol 10:194-202, 1990